Original research| Volume 8, ISSUE 3, P256-264, October 2014

Download started.


Comparison of efficacy and safety of once- versus twice-daily insulin detemir added on to oral antidiabetics in insulin-naive type 2 diabetes patients: 24-week, crossover, treat to target trial in a single center

Published:February 11, 2014DOI:



      To compare once- versus twice-daily insulin detemir added on OADS therapy in insulin-naive type 2 diabetes patients in terms of efficacy and safety.


      An open-label study performed at a single center, comprised a randomized, crossover 24 week with insulin-naive type 2 diabetes patients. Insulin detemir was initiated with mean 0.12 U/kg in all patients (Group I once-daily, Group II twice-daily) and titrated for 24 week.


      A total of 50 patients completed the study (Group I n:25, Group II n:25). With use of once- and twice-daily insulin, HbA1c values were decreased by 1.8% (±2.0) and 1.5% (±1.4) within the first 12 weeks (p < 0.01), whereas increased by 0.21% (±0.7) and 0.14% (±0.8) in the second 12 weeks (p > 0.05). The increases in the insulin doses were found as 0.22 U/kg and 0.35 U/kg with once- and twice-daily insulin use, respectively (p:0.04). Although minor hypoglycemic events were similar in both groups in the first 12 weeks, 2-fold increase was found in the patients shifting from once- to twice-daily dose. Within the first and second periods, the body weight of the patients was observed an increase of 0.4 and 1.6 kg with once-daily dose, whereas a decrease of 0.1 and 2.1 kg in the twice-daily dose, in the same period.


      Once-daily use of insulin detemir up to 0.4 U/kg was found to have similar efficacy and safety as twice-daily use. Twice dose use of insulin did not provide a prominent glycemic control advantage on 1.5-fold higher use of insulin.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Primary Care Diabetes
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Polonsky K.S.
        • Given B.D.
        • Hirsch L.J.
        • et al.
        Abnormal patterns of insulin secretion in non-insulin dependent diabetes mellitus.
        N. Engl. J. Med. 1988; 318: 1231-1239
        • UK Prospective Diabetes Study Group
        Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).
        Lancet. 1998; 352: 837-853
        • Heise T.
        • Nosek L.
        • Ronn B.B.
        • et al.
        Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.
        Diabetes. 2004; 53: 1614-1620
        • Owens D.R.
        • Matfin G.
        • Monnier L.
        Basal insulin analogues in the management of diabetes mellitus: what progress have we made?.
        Diabetes Metab. Res. Rev. 2013; (in press)
        • Hartman I.
        Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence.
        Clin. Med. Res. 2008; 6: 54-67
        • Havelund S.
        • Plum A.
        • Ribel U.
        • et al.
        The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin.
        Pharm. Res. 2004; 21: 1498-1504
        • Plank J.
        • Bodenlenz M.
        • Sinner F.
        • et al.
        A doubleblind, randomized, dose–response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.
        Diabetes Care. 2005; 28: 1107-1112
      1. Levemir® (Insulin Detemir [rDNA Origin] Injection) [Prescribing Information].
        Novo Nordisk Inc., Princeton, NJ2009
        • Klein O.
        • Lynge J.
        • Endahl L.
        • Damholt B.
        • Nosek L.
        • Heise T.
        Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time–action profiles but less variability than insulin glargine in type 2 diabetes.
        Diabetes Obes. Metab. 2007; 9: 290-299
        • Nelson S.E.
        Detemir as a once-daily basal insulin in type 2 diabetes.
        Clin. Pharmacol. 2011; 3: 27-37
        • Le Floch J.P.
        • Lévy M.
        • Mosnier-Pudar H.
        • et al.
        Comparison of once-versus twice-daily administration of insulin detemir: used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes assessment of detemir administration in a progressive treat-to-target trial (ADAPT).
        Diabetes Care. 2009; 32: 32-37
        • DeVries J.H.
        • Nattrass M.
        • Pieber T.R.
        Refining basal insulin therapy: what have we learned in the age of analogs?.
        Diabetes Metab. Res. Rev. 2007; 23: 441-454
        • Rosenstock J.
        • Davies M.
        • Home P.D.
        • Larsen J.
        • Koenen C.
        • Schernthaner G.
        A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes.
        Diabetologia. 2008; 51: 408-416
        • Raskin P.
        • Gylvin T.
        • Weng W.
        • Chaykin L.
        Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes.
        Diabetes Metab. Res. Rev. 2009; 25: 542-548
        • Luddeke H.J.
        • Sreenan S.
        • Aczel S.
        • et al.
        PREDICTIVE – a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort.
        Diabetes Obes. Metab. 2007; 9: 428-434
        • Dornhorst A.
        • Lüddeke H.J.
        • Koenen C.
        • et al.
        Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE™.
        Diabetes Obes. Metab. 2008; 10: 75-81
        • Fontaine P.
        • Gin H.
        • Pinget M.
        • et al.
        Effect of insulin detemir dose frequency on clinical outcomes in patients with diabetes in PREDICTIVE.
        Adv. Ther. 2009; 26: 535-551
        • Meneghini L.F.
        • Rosenberg K.H.
        • Koenen C.
        • Merilainen M.J.
        • Luddeke H.J.
        Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study.
        Diabetes Obes. Metab. 2007; 9: 418-427
        • Hermansen K.
        • Lund P.
        • Clemmensen K.
        • et al.
        3-Month results from Denmark within the globally prospective and observational study to evaluate insulin detemir treatment in type 1 and type 2 diabetes: the PREDICTIVE study.
        Rev. Diabet. Stud. 2007; 4: 89-97
        • Dornhorst A.
        • Luddeke H.J.
        • Sreenan S.
        • et al.
        Insulin detemir improves glycaemic control without weight gain in insulin–naive patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study.
        Int. J. Clin. Pract. 2008; 62: 659-665
        • Brunner G.A.
        • Sendhofer G.
        • Wutte A.
        • et al.
        Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans.
        Exp. Clin. Endocrinol. Diabetes. 2000; 108: 100-105
        • O’Connor P.J.
        • Fragneto R.
        • Coulehan J.
        • Crabtree B.F.
        Metabolic control in noninsulin-dependent diabetes mellitus: factors associated with patient outcomes.
        Diabetes Care. 1987; 10: 697-701
        • Wolffenbuttel B.H.
        • Landgraf R.
        A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group.
        Diabetes Care. 1999; 22: 463-467